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A B S T R A C T
Prostaglandins (PGs) are important regulators of the early corpus luteum (CL) in the dog. Whereas, initially, CL is
gonadotropin independent, in the second half of its lifespan, hypophyseal support is required. The transition
period is marked by decreased availability of PGs, in particular of PGE2. We previously reported that inhibition
of COX2/PTGS2 in vivo suppressed luteal production of PGE2, lowered circulating progesterone and negatively
affected luteal development. Therefore, bitches were treated with a COX2-specific blocker, firocoxib, for 5, 10,
20 and 30 days after ovulation, leading to suppression of the steroidogenic machinery. Control groups received a
placebo for the same periods. Considering the wide range of possible modulatory roles of PGs shown in different
organ systems, this follow-up project aimed to understand further possible PG-mediated effects in early canine
CL. Thirty-four (34) factors related predominantly to vascularization and immune response were screened
(mRNAs and proteins) on samples from the above described in vivo study. Most of the effects were observed
during the transitional period (days 20 and 30). The inhibition of COX2 diminished the expression of angio-
poietin family members ANGPT1, -2, Tie1 and -2 receptors. The expression of endothelin (ET)-1 was increased.
Concerning the immune system, increased expression of the pro-inflammatory cytokines, IL1β, IL6 and IL12a,
and elevated expression levels of CD4, was observed. Cumulatively, besides its involvement in regulating ster-
oidogenesis, our results indicate a broader role of PGs in the canine CL, including modulation of angiogenesis,
vascular stabilization and local immunomodulation. Possible cross-species translational effects are strongly
implied.
1. Introduction
The corpus luteum (CL) is a temporary endocrine gland which, by
producing progesterone (P4), exerts important roles in the reproduction
of mammals. It is formed from the remnants of the ruptured follicle and
grows rapidly to ensure an adequate steroid supply for the establish-
ment and maintenance of pregnancy. This rapid development and
steroidogenic activity require the support of rapidly developed and
dense vascularization [1,2]. Also, immune system-derived factors ap-
pear to have an important role in CL formation and function [3].
Prostaglandins (PGs) are among the most prominent regulators of CL
function across mammalian species, with PGE2 and PGF2α typically
playing opposing roles. Thus, the luteotropic function of luteal PGE2 is
mostly opposed to the luteolytic effects of PGF2α. The function of PGE2
is mostly concerned with the cAMP/PKA-mediated stimulation of STAR
(steroidogenic acute regulatory protein) expression and function [4,5].
Interestingly, however, some other effects of PGE2 in the CL have been
described lately, e.g., with regard to vascularization. Accordingly, e.g.,
in the pig, PGE2 increases the secretion of luteal VEGF [6].
In the domestic dog, circulating progesterone (P4) originates in the
CL, both in pregnant and non-pregnant bitches, thereby acquiring a
central role in the regulation of diestrus/pregnancy [7]. When com-
pared with other domestic animal species, canine luteal physiology
appears quite peculiar. Thus, in contrast to livestock, a uterine luteo-
lysin (PGF2α) does not exist in non-pregnant bitches, as clearly shown
in hysterectomized females which maintain their normal ovarian
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function [8]. Similarly, the presence of an intraluteal luteolytic prin-
ciple can be ruled out, as there is no luteolysis in the absence of preg-
nancy in the dog. The intraluteal levels of PGF2α are low [9,10], but
the respective receptor (FP/PTGFR) appears, however, to be con-
stitutively expressed [9,11], reaching its highest abundance in the
second half of diestrus, and rendering the canine CL receptive to exo-
genously applied PGF2α. Consequently, the lack of luteolysis in non-
pregnant, cyclic bitches results in a prolonged pseudopregnancy, fre-
quently lasting longer than pregnancy itself [4,8]. With this, cumula-
tively, the luteal regression in non-pregnant dogs appears to be a long-
lasting process of structural remodelling and functional degeneration,
devoid of an active luteolytic principle [5]. Conversely, in pregnant
dogs, the cessation of luteal function is associated with an increased
presence of utero-placental PGF2α in the maternal circulation, strongly
implying its luteolytic function [7,12].
With regard to species-specific regulatory mechanisms, main-
tenance of the mature canine CL depends strongly on hypophyseal
hormones, with prolactin (PRL) acting as the predominant luteotropic
factor during the second half of diestrus, starting around 4 weeks after
ovulation [13–15]. During earlier stages of the luteal phase, hypophy-
seal support does not seem necessary [14] and, at least in part, the CL is
gonadotropin independent. At this time, increased expression of luteal
cyclooxygenase 2 (COX2/PTGS2), as well as of PGE2 synthase (PTGES)
and two cAMP/PKA-mediating PGE2 receptors (EP2/PTGER2 and EP4/
PTGER4) in luteal cells, suggests the importance of PGs and in parti-
cular of PGE2 as autocrine/paracrine regulators of early CL function in
the dog [16,17]. Supporting this idea, in vitro stimulation of early ca-
nine luteal cells with PGE2 increases the expression of STAR protein
and potentiates P4 synthesis [4]. In our previously published studies,
the luteotropic role of PGs in the early canine CL was further sub-
stantiated in vivo [10,18]. Thus, bitches treated with a specific inhibitor
of COX2/PTGS2, firocoxib, for up to 30 days after ovulation, exhibited
lower levels of intra-luteal PGE2, accompanied by downregulated ex-
pression of PTGES and steroidogenesis-linked factors (STAR and
3βHSD), and lowered circulating levels of P4 [10,18]. Interestingly, in a
parallel in vitro experiment, it was shown that PGE2 positively regulates
expression of the prolactin receptor (PRLR) in canine lutein cells. With
that previous study [10], a causality has been indicated between
PTGS2/COX2 function and the PTGES-dependent synthesis of PGE2,
and luteal P4 synthesis in the dog.
As mentioned elsewhere, the development and activity of CL rely on
rapid development of a dense vascular network. Accordingly, also in the
dog, the luteal expression of VEGFA and VEGFR1 is upregulated in early
CL of pregnant and non-pregnant bitches [19,20]. Furthermore, va-
soactive factors from the endothelins family are present in the canine
CL and are expressed in a time-dependent manner throughout the CL
life span [21]. Thus, the early luteal phase is characterized by elevated
levels of endothelin 2 (ET2), endothelin receptor B (ETB) and the en-
dothelin converting enzyme 1 (ECE1) that regulates the availability of
endothelins [21]. It is noteworthy in this context that, in one of our
previous studies, PGE2 was shown to upregulate in vitro luteal expres-
sion of the vasodilatory endothelin receptor B (ETB) in the dog [21].
The effects of PGE2 on the expression of VEGFA and the endothelin-
system have, however, never been assessed in vivo. The functionality of
the vasculature appears to be also affected during prepartum luteolysis,
as implied by the increased expression of vasoconstrictive endothelin A
receptor (ETA) [21]. No such effects could be observed for the CL of
non-pregnant dogs during late luteal regression [21,22].
With regard to the immune system, apart from its indicated in-
volvement in termination of luteal function in pregnant dogs [22], the
development of the CL is also associated with increased activity of
immune system-derived factors. This is indicated by the increased in-
filtration of immune cells [23], as well as increased expression of dif-
ferent chemokines (e.g., tumor necrosis factor alpha; TNFα [24]). Ac-
cordingly, increased numbers of CD4, CD8 and endoglin (END) positive
cells were observed in the CL of pregnant and non-pregnant cycles
[23,24] during luteal formation. Additionally, the expression of several
cytokines has been confirmed in canine luteal tissue, e.g., interleukin
(IL) 8, IL10, IL12a, TNFα or transforming growth factor 1 beta (TGF1β)
[24–26]. Nevertheless, the exact role of these factors in the develop-
ment and maintenance of the canine CL remains to be elucidated.
In this context, adding to the possible roles of PGE2 in maintaining
tissue homeostasis, both pro- and anti-inflammatory mechanisms have
been described for this prostaglandin in different tissues [27,28]. In the
reproductive system, PGE2 was shown to modulate immune activity in
a suppressive manner in the human uterus [29]. These effects seem to
support feto-maternal immune tolerance. In other tissues, e.g., the lung,
PGE2-induced immunomodulation is linked to control of inflammation
and limitation of damage during prolonged immune responses [27,30].
However, to the best of our knowledge, nothing is known about im-
munomodulatory effects that PGE2 and other PGs could exert in the
early canine CL.
Here, taking into account the so far known effects exerted by PGs
upon different regulatory systems in vitro, and the effects resulting from
firocoxib treatment and, thereby, the suppression of PGs function in
vivo, we hypothesized that PGs could also have other biological effects
in the early canine CL. Therefore, using the tissue material from our
above mentioned previous studies [10,18], we investigated the possible
impact of blocking COX2/PTGS2 on vascular and immune functions
during establishment and development of the canine CL. The expression
of 34 different potential target genes known for their involvement in
regulating CL function was screened.
2. Materials and methods
2.1. Tissue samples
This is a follow up project utilizing tissue samples obtained in our
previously described in vivo study [10,18], approved by the responsible
ethics committee of the University of Warmia and Mazury in Olsztyn,
Poland (permit 54/2008).
In brief, middle-sized mixed breed bitches aged 2 to 7 years were
observed for the onset of spontaneous estrus by vaginal cytology and P4
assay. The day of ovulation (Day 0) was considered the day when cir-
culating P4 concentrations for the first time exceeded 5 ng/ml. The
animals were then randomly assigned (simple randomization) to four
treatment groups and five control groups. Bitches from treated groups
received, orally, 10mg/kg body weight per day (twice the re-
commended dose) of firocoxib (Previcox®, Merial Ltd), a COX2/PTGS2
specific inhibitor, for 5 (n=4), 10 (n= 4), 20 (n=3) and 30 (n=5)
days. Animals from control groups received a placebo for 0 (n= 5), 5
(n= 5), 10 (n= 4), 20 (n=3) and 30 (n= 4) days. With this, samples
used in our study derive from different stages of early luteal develop-
ment in the dog, i.e., developing gonadotropin-independent CL (days 5
and 10), mature CL in transition between gonadotropin independency
and dependency (day 20) and mature gonadotropin-dependent CL (day
30) [5,13–15]. This allowed further analysis of the effects of time on the
expression of the studied target genes. On the last day of treatment,
animals were ovariohysterectomized for collection of ovaries con-
taining CLs. The corresponding P4 levels are presented in [10,18].
Ovaries were then immediately trimmed of surrounding connective
tissue and divided into two parts. CLs from one part were preserved for
mRNA analysis, being placed in RNAlater (Ambion Biotechnology
GmbH, Wiesbaden, Germany) for 24 h at 4 °C and then stored in −80 °C
until further use. The second half of the ovary was fixed in 10%
phosphate-buffered formalin for 24 h at 4 °C and then paraffin em-
bedded using standard methodology.
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2.2. Total RNA extraction, high capacity reverse transcription (RT) and
pre-amplification of cDNA
Extraction of total RNA from all samples was performed using
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following the manu-
facturer’s protocol. RNA concentration and purity were measured with
a Nano Drop 2000C spectrophotometer (Thermo Fisher Scientific AG,
Reinach, Switzerland).
Samples were diluted and a total amount of 10 ng of RNA was used
from each sample. To eliminate possible genomic DNA contamination,
all samples were treated with the RQ1 RNase-free DNase kit (Promega,
Dübendorf, Switzerland) following the manufacturer’s protocol.
Reverse transcription (RT) was performed using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems by Thermo Fisher
Scientific, Foster City, CA, USA), following the supplier’s protocol, ob-
taining cDNA in a final volume of 20 μl. Finally, the amount of cDNA
was amplified with the TaqMan® PreAmp Master Mix Kit (Applied
Biosystems). For this, pooling of TaqMan assays for all selected target
genes and reference genes was prepared in a 250 μl mix containing:
180 nM of each forward and reverse primer and 50 nM of probe for
commercially available TaqMan assays, and 15 nM of each forward and
reverse primer and 20 nM of each probe for self-designed TaqMan
systems. For subsequent amplification, 12.5 μl of the previously pre-
pared cDNA from each sample was mixed with 25 μl of 2x TaqMan
Preamp Master Mix and 12.5 μl of the pooled TaqMan assays mix.
Enzymes were activated at 95 °C for 10min and then samples were
amplified through 14 cycles of 95 °C for 15 s and 60 °C for 4min, each.
All reactions were performed in an Eppendorf Mastercycler (Vaudax-
Eppendorf AG, Basel, Switzerland).
2.3. Semi-quantitative real-time TaqMan PCR (qPCR) and data evaluation
Semi-quantification of luteal expression of 34 selected target genes
was assessed by real-time (TaqMan) PCR.
For each sample and target gene, 25 μl of reaction mixture was
prepared, containing 200 nM TaqMan Probe, 300 nM of each primer,
12.5 μl Fast Start Universal Probe Master (ROX®) (Roche Diagnostics,
Mannheim, Germany) and 5 μl of pre-amplified cDNA obtained as de-
scribed above. All reactions were run in duplicates in 96-well optical
plates. Autoclaved water instead of cDNA and the minus-RT control
were run as negative controls. A detailed description of primers,
TaqMan probes and predesigned (i.e., commercially available) TaqMan
systems, as well as all gene names and their corresponding abbrevia-
tions are presented in Suppl. File 1. Self-designed primers and 6-car-
boxyfluorescein (6-FAM) and 6-carbocytetramethylrhodamine
(TAMRA) labelled probes were ordered from Microsynth (Balgach,
Switzerland). Commercially-available TaqMan systems were obtained
from Applied Biosystems. Efficiency values of the PCR reactions were
validated to ensure approximately 100%. For this, the CT slope method
was performed, using as the template cDNA obtained from CL of two
different stages and each diluted in a 10-fold series, according to the
instructions of the manufacturer and as previously described [31]. Real-
time PCR reactions were run in an automated ABI PRISM 7500 Se-
quence Detection System (Applied Biosystems). Reactions were acti-
vated at 95 °C for 10min, and then samples were amplified in 40 cycles
comprising of: 95 °C for 15 s and 60 °C for 60 s, each. Results were
quantified with the comparative CT (ΔΔCT) method according to the
protocol provided by the manufacturer of ABI PRISM 7500 and as de-
scribed previously [16,31]. The expression of the reference genes was
used for normalization of target gene expression and the lowest ex-
pression for each target gene was used as a calibrator. As for reference
genes, in pilot experiments, three genes (GAPDH, β-ACTIN and CYCL-
OPHILIN A) were initially evaluated, based on their expression in all
samples included in the study. Then, evaluation of reference gene sta-
bility was performed using two programs: geNorm and NormFinder
[32,33]. Finally, GAPDH was selected as the most stable gene,
compared with β-ACTIN and CYCLOPHILIN A, and was used as the
reference gene for the ΔΔCT evaluation.
To evaluate the effects of treatment on the expression of target
genes, an unpaired, two-tailed Student’s t-test was used, comparing
treatment group with control group, from each time point (day).
Additionally, time-related changes in the expression of all target genes
in control animals were evaluated using Kruskal-Wallis (non-parametric
ANOVA) followed by Dunn’s test. All numerical results for relative gene
expression were logarithmically transformed and are presented as
geometric means (Xg) +/- geometric standard deviation (SD). All sta-
tistical tests were performed with GraphPad3 (GraphPad Software Inc.,
San Diego, CA, USA); P < 0.05 was considered statistically significant.
2.4. Immunohistochemical staining
Depending on the availability of canine species-specific and/or
cross-reacting antibodies, immunohistochemistry (IHC) was performed
for those factors that showed a significant response to treatment at the
mRNA level. Thus, staining was performed against members of the
ANGPT system (ANGPT1, ANGPT2, TIE1 and TIE2), ET1 and CD4; more
details are listed below. Antibodies targeted against IL1β (NB600-633,
Novus Biologicals LLC, Littleton, CO, USA) and IL12a (Orb256618,
Biorbyt Ltd., Cambridge, UK) were also tested, but failed to produce
reliable staining. No commercially-available antibody against IL6 with
described/predicted cross-reactivity for the canine species was found.
The standard, indirect immunoperoxidase staining method was used
for IHC, following our previously published protocol with canine tissues
[16]. Briefly, formalin-fixed and paraffin-embedded luteal tissues were
cut on a microtome (2–3 μm thick sections), transferred to SuperFrost
microscope slides (Menzel-Glaeser, Braunschweig, Germany) and dried
overnight at 37 °C. At least 5–6 slides were analysed from each animal.
The tissue slices were then deparaffinized with xylene and rehydrated
in a graded ethanol series, ending with tap water. Antigen retrieval was
obtained by microwave heating in citrate buffer (pH=6) for three
cycles of 5min at 600W. Endogenous peroxidase activity was blocked
with 0.3% hydrogen peroxide in methanol. Slides were washed in IHC
buffer/0.3% Triton X pH 7.2–7.4 (0.8 mM Na2HPO4, 1.74mM KH2PO4,
2.68mM KCl, 137mM NaCl), and incubated in 10% normal horse
serum (for TIE2, ET1 and CD4), or 10% normal goat serum (for
ANGPT1, ANGPT2 and TIE1), for 20min at ambient temperature to
reduce non-specific binding. Additional blocking with 1.5% bovine
serum albumin was performed for 5min for CD4. Finally, samples were
incubated overnight at 4 °C with the following primary antibodies at
respective dilutions: anti-ANGPT1 (PAA008Ca01, Cloud-clone Corp.,
Houston, TX, USA), 1:50; anti-ANGPT2 (TA343276, OriGene Technol-
ogies Inc., Rockville, MD, USA), 1:400; anti-TIE1 (sc-9025, Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA), 1:100; anti-TIE2 (sc-31268,
Santa Cruz Biotechnology Inc.) 1:200; anti-ET1 (SIGMA-E166, Sigma-
Aldrich, St. Louis, MO, USA), 1:600; anti-CD4 (GTX84720, GeneTex,
Irvine, CA, USA), 1:600. Afterwards, samples were incubated in sec-
ondary antibody diluted 1:100 (BA-100 biotinylated goat anti-rabbit
IgG for ANGPT1, ANGPT2 and TIE1; BA-9500 biotinylated horse anti-
goat IgG for TIE2; BA-2000 biotinylated horse anti-mouse IgG for ET1
and CD4; all from Vector Laboratories Inc., Burlingame, CA, USA) for
30min at ambient temperature, followed by incubation with strepta-
vidin-peroxidase Vectastain ABC kit (Vector Laboratories Inc.) for
30min at room temperature. Signals were developed with the Liquid
DAB+ substrate kit (Dako Schweiz AG, Baar, Switzerland). For each
antibody, all groups were simultaneously stained using the same de-
velopment time. Slides were counterstained with hematoxylin, dehy-
drated in a graded ethanol series and mounted in Histokit (Assistant,
Osterode, Germany). For negative controls, sections were incubated
with non-immune IgG instead of primary antibodies, from the same
species and at the same concentration as the primary antibody (isotype
control): rabbit IgG (I-1000) for ANGPT1, ANGPT2 and TIE1, goat IgG
(I-5000) for TIE2 and mouse IgG (I-2000) for ET1, all from Vector
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Laboratories Inc., and mouse IgG1 for CD4 (ABIN376357, Antibodies-
Online GmbH, Aachen, Germany). An additional control was comprised
of sections omitting the primary antibody.
Slides were evaluated under a Leica DMRXE light microscope
equipped with a Leica DFC425 camera (Leica Microsystems, Wetzlar,
Germany). IHC slides were assessed qualitatively by two independent
researchers for localization of the respective target proteins and re-
presentative pictures were taken. Morphological identification of cel-
lular components within the CL, including immune cell differentiation,
was based on available histologic literature [34,35], as well as on in-
formation available from the canine literature, and on the herein ob-
served luteal distribution of CD4 expressing cells that corroborates
previously published findings [5,23,24,36]. In particular, the localiza-
tion of CD4 positive signals could be predicted by their typical cellular
localization, which was described previously for the dog as being lo-
calized in monocytes and macrophages [23,24], thereby serving as a
positive internal control.
3. Results
3.1. Semi-quantification of target gene expression
The expression of almost all target genes was detectable in all tissue
material available. The only exception was for endothelin 3 (ET3),
whose expression was frequently below the detection limit, preventing
quantitative assessment of its expression. Also, a relatively high in-
dividual variability in the expression of some of the studied factors was
observed. Despite that, as presented below, treatment and/or time-re-
lated changes in the expression of several genes were observed (Fig. 1–3
and Suppl. File 2). On the other hand, no statistically significant
changes (P > 0.05) were observed for the following genes, neither in
their responses to treatment nor during the experimental time-course:
VEGFA, ETA, MHCII, CD8, IL8, TGF1β, TNFR1 and GATA4 (Suppl. File
3).
3.2. Effects of treatment on target gene expression
Of the 33 detectable factors, effects of Previcox® treatment on mRNA
expression were observed on 11: the angiopoietin (ANGPT)-family
members (ANGPT1, ANGPT2, TIE1 and TIE2), as well as ET1, CD4, IL1β,
IL6, IL12a, cJUN and CCNA2. Thus, ANGPT1 expression was sig-
nificantly decreased on day 20 in the treated group (P < 0.05, Fig. 1A)
while ANGPT2 (P < 0.0001, Fig. 1B), TIE1 (P < 0.04, Fig. 1C) and
TIE2 (P < 0.04, Fig. 1D) were decreased on day 30 after ovulation,
compared with placebo-treated controls. Conversely, ET1 expression
was increased by treatment on day 20 (P < 0.03, Fig. 2A). As for im-
mune factors, whereas the expression of CD4 was increased on day 30
(P < 0.03, Fig. 2B) by the treatment, mRNA levels of IL1β (P < 0.04,
Fig. 2C), IL12a (P < 0.002, Fig. 2D) and of IL6 (P < 0.02, Fig. 2G)
were elevated on day 20. Finally, the expression of cJUN (P < 0.01,
Fig. 3A) and CCNA2 (P < 0.01, Fig. 3B) was also increased at day 20
after ovulation in CL of treated animals. The expression of some of the
factors varied greatly in CL of treated animals, e.g., both estrogen re-
ceptors, ERα/ESR1, and in particular ERβ/ESR2 or TNFα, but their ex-
pression levels were not significantly affected by the treatment
(P > 0.05) (Suppl. File 2).
At the protein level, ANGPT1 was detected in endothelial cells and
tunica media and pericytes of blood vessels (Fig. 1E). Whereas ANGPT2
was clearly detectable in luteal cells (Fig. 1F), only weak or no signals
were detected for ANGPT1 in these cells (Fig. 1E). Additionally, signals
for both angiopoietins were detected in interstitial cells identified as
luteal macrophages. The expression of ANGPTs in the canine luteal
macrophages was verified previously on consecutive sections stained
for MHCII/ANGPT2 [36] in the CL of pregnancy. As for angiopoietin
receptors, signals for TIE1 were observed in tunica intima (endothelial
cells), tunica media and pericytes of vessels, macrophages and in luteal
cells (Fig. 1G), while TIE2 was predominantly localized in vascular
endothelial cells and tunica media/pericytes of vessels (Fig. 1H). The
only member of the endothelin family affected by the treatment, ET1,
was localized in luteal cells (Fig. 2E). Finally, CD4-positive cells were
identified as monocytes/macrophages (Fig. 2F). Also, this localization
pattern of CD4 in immune cells of canine CL was verified previously
[24]. In general, the effects of treatment observed at the IHC level
appeared to mirror their expression levels observed by qPCR. This was
particularly obvious for ANGPT2 at day 30 and for ET1 at day 20. An
apparent increase in the number of CD4-positive cells present in CL was
observed, mainly in regions surrounding blood vessels.
3.3. Time-related changes in gene expression
Time-related changes in target gene expression were assessed in all
control groups from the time of ovulation through early diestrus.
During the observation period, the expression pattern of several factors
affected by the treatment, ANGPT2, TIE1, TIE2, CD4 and CCNA2, was
time-dependent (P=0.0015, P=0.0001, P=0.009, P=0.01, and
P= 0.001, respectively) (Figs. 1–3).
Over time, expression of ANGPT2 and of its receptors, TIE1 and -2,
increased. The expression of ANGPT2 and TIE1 was significantly higher
on days 20 and 30 than during early CL formation (P < 0.05, Fig. 1B
and C), while the expression of TIE2 was significantly higher on day 20
compared with the day of ovulation (P < 0.05, Fig. 1D). CD4 expres-
sion was more stable in early luteal stages, but it was significantly
higher at day 20 than day 30 after ovulation, when its expression was
significantly downregulated (P < 0.01, Fig. 2B). Finally, representa-
tion of the cell cycle regulator CCNA2 was relatively higher in early CL,
showing the highest mRNA levels at day 5 and decreasing significantly
by day 20 after ovulation (P < 0.01, Fig. 3B).
Time-related effects in gene expression were also observed in sev-
eral target genes that were not affected by the treatment: ETB
(P= 0.005), ET2 (P= 0.03), ECE1 (P=0.03), eNOS (P= 0.02), iNOS
(P= 0.02), ERα/ESR1 (P=0.01), ERβ/ESR2 (P= 0.001), YY1
(P= 0.002), SF1 (P=0.004), GATA6 (P=0.002), END (P=0.01),
IL10 (P= 0.03), TNFα (P=0.008) and TNFR2 (P= 0.01) (Suppl. File
2). Additionally, summary of the respective results is presented in
Table 1.
The expression of ETB increased rapidly after ovulation, being sig-
nificantly lower at the time of ovulation than at any other evaluated
time points thereafter (P < 0.05, Table 1, Suppl. File 2A). In contrast,
ET2 decreased after ovulation, reaching its lowest expression on day 10
(P < 0.05, Table 1, Suppl. File 2B). Finally, the levels of mRNA en-
coding for ECE1 showed significantly increased levels on days 20 and
30 compared with the day of ovulation (P < 0.01) and day 10
(P < 0.05, Table 1, Suppl. File 2C). Functionally related to the en-
dothelin-system, expression of eNOS (endothelial nitric oxide synthase)
and iNOS (inducible NOS) was lowest on the day of ovulation, while
eNOS expression increased significantly towards day 20 (P < 0.05,
Table 1, Suppl. File 2D), and on days 20 and 30 for iNOS (P < 0.05,
Table 1, Suppl. File 2E). The expression of ERα/ESR1 increased sig-
nificantly between the day of ovulation and day 30 (P < 0.05 for ERα),
whereas ERβ/ESR2 expression was significantly higher on day 30 than
on day 10 after ovulation (P < 0.01) (Table 1, Suppl. File 2F and G).
The levels of mRNA encoding for the transcriptional factors and known
regulators of STAR expression, YY1 and SF1, increased significantly
after ovulation, with the highest expression on day 20 for YY1
(P < 0.01, Table 1, Suppl. File 2H), and on days 20 and 30 for SF1
(P < 0.05, Table 1, Suppl. File 2I). In contrast, GATA6 exhibited sig-
nificantly higher expression on day 5 than on days 20 and 30 (P < 0.01
and P < 0.05, respectively, Table 1, Suppl. File 2J). As for the immune
factors, END mRNA levels increased significantly over time, from the
day of ovulation towards day 30 (P < 0.01, Table 1, Suppl. File 2K).
The opposite expression pattern was observed for IL10, TNFα and its
receptor TNFR2 which showed the highest mRNA abundance on day 5
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after ovulation, decreasing significantly towards either day 20 (TNFα,
P < 0.05, Table 1, Suppl. File 2M) or day 30 (IL10 and TNFR2,
P < 0.05, Table 1, Suppl. File 2L and N, respectively).
4. Discussion
A plethora of roles has been attributed to PGs in mammals, in-
cluding those roles less studied with respect to the reproductive tract,
such as immunomodulation/suppression or vasodilation and
(caption on next page)
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vasoconstriction. As for the CL of the dog, in particular PGE2 is con-
sidered to be among the important regulators in the early, gonado-
tropin-independent developmental stage. Its function has been asso-
ciated predominantly with cAMP-dependent regulation of
steroidogenesis [5]. Consequently, based on the possible causality im-
plied in our previous studies between COX2/PTGS2 activity and the
functionality of PGE2 in Previcox-treated dogs [10,18], here, other
potential biological effects exerted by PGs in the canine CL were in-
vestigated. The main focus was on the vascular and immune systems.
Thus, a wide range of factors possibly involved in the regulation of
luteal function was screened for their expression during the normal
early luteal phase and following application of Previcox. According to
our knowledge, some of these factors were thoroughly studied and/or
quantitatively assessed for the first time in the early canine CL, e.g.,
IL1β, IL6, IL12a, IL10, eNOS and iNOS. Additionally, the expression of
some other factors involved in the establishment and maintenance of CL
function was examined, such as ERα/ESR1 and ERβ/ESR2, or tran-
scriptional regulators of STAR: GATA4 and -6, SF1, cJUN and YY1.
Despite large individual variations in the expression of most of the in-
vestigated factors upon treatment with Previcox (discussed in more
detail later), several of them were identified as being strongly affected
by PGs withdrawal.
4.1. Vascular factors
Among the vascular factors, the ANGPT system was the most
strongly affected by Previcox treatment in our study. This study is the
first to show expression of the ANGPT system during CL development in
non-pregnant dogs. Its expression in the CL of pregnant dogs was shown
recently [36]. Whereas the expression of ANGPT1 was time-dependent,
showing strong decrease towards prepartum luteolysis, the expression
of ANGPT2 remained highly expressed and clearly detectable over time
[36]. Similarly, in the herein presented study, CL formation was asso-
ciated with increasing mRNA levels of ANGPT2 and the two receptors,
TIE1, and TIE2. The expression of ANGPT1 remained more or less stable
during the 30 days of luteal development of non-pregnant dogs. Con-
sistent with our previous findings with CL of pregnancy [36], the ex-
pression of ANGPT1 was targeted to luteal vessels, whereas ANGPT2
was localized mainly in luteal cells. Also, interstitial cells and cells
identified as local macrophages [24,34–36], were identified as a pos-
sible source of ANGPTs in the canine CL. Both receptors were pre-
dominantly localized in the vascular components of the CL, pointing
towards functional interplay of the ANGPT family members in reg-
ulating the canine CL. Acting together with VEGFA, and utilizing their
tyrosine kinase receptors, TIE1 and TIE2, ANGPTs regulate vascular
stability [37–40]. Whereas ANGPT1 promotes vascular stabilization
and prevents uncontrolled angiogenesis [37,38], ANGPT2 in the pre-
sence of abundant concentrations of VEGFA (e.g., during the early lu-
teal phase) causes destabilization/loosening of blood vessels and sup-
ports migration of endothelial cells, enhancing angiogenesis [2,41]. The
results of our study indicate that the negative effects of Previcox
treatment on expression of ANGPT family members point towards
modulatory effects of PGs on luteal angiogenesis and vessel stabiliza-
tion. Taking into consideration the cellular distribution of ANGPTs and
their receptors in Previcox treated animals, we propose that PGs have
stimulatory effects on the ANGPT system in different luteal cellular
compartments.
Interestingly, the expression of VEGFA was not affected by the
treatment in the present study. Thus, the functional connection between
locally acting PGs, in particular PGE2, and the VEGF system, estab-
lished previously for the pig and rat CL [6,42], does not seem to apply
in the dog.
Furthermore, adding to the positive effects exerted by PGE2 on ETB
expression in isolated canine lutein cells [21], here we observed mod-
ulatory effects of PGs withdrawal on ET1. In agreement with our pre-
vious study [21], ET1 in the canine CL was localized in lutein cells.
Endothelins play important roles in the regulation of several ovarian
functions such as vascularization, steroidogenesis, ovulation, folliculo-
genesis, luteal regression and luteolysis [43,44]. Besides ET1, they are
represented by ET2 and ET3, and upon activation by the specific con-
verting enzyme (ECE1), endothelins exert their ETA- and ETB-mediated
effects, the latter involving activation of the nitric oxide (NO) pathway
[45,46]. Here, although ETB expression seemed to be lowered by Pre-
vicox treatment, these changes were not statistically significant, most
probably due to high individual variations.
Taking into account, however, the above-mentioned effects of PGE2
on ETB expression and the stimulatory effects exerted by PGs sup-
pression on ET1 expression, it seems that the role of PGs in regulating
the expression and function of luteal endothelins is a topic worthy of
more attention in future research. In addition, ET1 has been linked to
luteolytic processes in several species, e.g., in ruminants, rats and
rabbits [47–50]. Similarly, along with the vasoconstrictive ETA, the
expression of ET1 was strongly increased in our previous study in which
a PGR blocker was applied for pregnancy termination in mid-pregnant
dogs [21].
On the other hand, in accordance with our previous findings, CL
development was characterized by increased intraluteal levels of ETB
and ECE1 [21]. The increased vascularization observed during this time
was also mirrored in increasing expression of endoglin (END), which is
a phenomenon described previously for the CL of both pregnant and
non-pregnant dogs [23,24]. Similarly, expression of the respective NO
synthases, eNOS and iNOS, known for their involvement in regulating
luteal function in other species, such as cattle or rats [51–53], increased
significantly with progression of the luteal phase. In the present study,
however, their expression was unaffected by Previcox treatment.
4.2. Immune factors
The early luteal phase in the dog is associated with increased in-
filtration of CD4- and CD8-positive cells, mostly representing macro-
phages, monocytes and lymphocytes [23,24]. Their presence and dis-
tribution within the CL of pregnant and non-pregnant dogs has been
described before [23,24]. Particularly for CD4 expression, we were able
to confirm these previous observations in the present study. A new
finding from our study was, however, the increased expression of CD4
in the CL of Previcox treated animals. As for other mediators of the
immune response, the pro-inflammatory IL1β and IL12a did not vary
strongly individually nor with regard to the stages of early CL
Fig. 1. Expression of ANGPT1, ANGPT2, TIE1 and TIE2 in luteal tissue of control and Previcox-treated dogs. (A–D) Relative target gene expression as
determined by Real Time (TaqMan) PCR (Xg ± SD). The Kruskal–Wallis (non-parametric ANOVA) was applied to test the effects of time on gene expression in all
control samples, revealing: P > 0.05 for ANGPT1, P=0.0015 for ANGPT2, P= 0.0001 for TIE1 and P=0.009 for TIE2. This, in case of P < 0.05, was followed by
Dunn’s multiple comparison post-test (dotted lines). Student’s t-test was applied to test the effect of treatment on gene expression (solid lines). Bars with asterisks
differ at: * =P < 0.05, ** =P < 0.01, *** =P < 0.001. (E–H) Immunohistochemical localization of respective proteins; representative pictures are shown at
selected time points after ovulation. (E) ANGPT1 protein is detected in endothelial cells (open arrows), tunica media or pericytes of vessels (solid arrowheads) and
macrophages (open arrowheads). Weaker or no signals are detected in luteal cells (solid arrows). (F) ANGPT2 protein is localized predominantly in luteal cells (solid
arrows) and luteal macrophages (open arrowheads). (G) TIE1 localizes in endothelial cells (open arrows), tunica media or pericytes of vessels (solid arrowheads),
macrophages (open arrowheads) and luteal cells (solid arrows). (H) TIE2 stains in endothelial cells (open arrows) and tunica media or pericytes (solid arrowheads).
Weaker or no signals are detected in luteal cells (solid arrows). No staining is observed in the isotype control (left bottom pictures in E–H, shown at the same
magnification).
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Fig. 2. Expression of ET1, CD4, IL1β, IL6 and IL12a in luteal tissue of control and Previcox-treated dogs. (A–D and G) relative target gene expression as
determined by Real Time (TaqMan) PCR (Xg ± SD). The Kruskal-Wallis (non-parametric ANOVA) was applied to test the effects of time on gene expression in all
control samples, revealing: P > 0.05 for ET1, IL1β, IL6 and IL12a, and P= 0.01 for CD4. This, for CD4, was followed by Dunn’s multiple comparison post-test (dotted
line). Student’s t-test was applied to test the effect of treatment on gene expression (solid lines). Bars with asterisks differ at: *=P < 0.05; **=P < 0.01. (E–F)
Immunohistochemical localization of ET1 and CD4; representative pictures are shown at selected time points after ovulation. (E) ET1 protein is localized in luteal
cells (solid arrows). (F) CD4 protein is localized in monocytes/macrophages (open arrowheads); lutein cells are indicated by solid arrows. No staining is observed in
the isotype control (left bottom pictures in E and F, shown at the same magnification).
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development. The expression of IL6 seemed to be lower at day 20 and
30, but also these effects were not statistically significant. With regard
to Previcox treatment, like for CD4-expressing cells, the expression of
all three pro-inflammatory cytokines (IL1β, IL12a and IL6) was sig-
nificantly increased. This was, indeed, an interesting discovery from our
study as it indicates modulatory, possibly immunosuppressive, effects
of PGs in the canine CL. The pro-inflammatory properties of IL1β in the
CL of the dog were recently implicated in our transcriptome studies,
revealing its increased presence in apoptosis-dominated CL during pre-
partum luteolysis [22]. Conversely, the elevated expression of IL10
during early CL development, at day 10 after ovulation, indicates its
possible luteotropic function, resembling thereby the situation de-
scribed previously for human luteal cells, in which IL10 was shown to
stimulate P4 production [54].
Finally, whereas the expression of TNFR1 was not significantly af-
fected in our study, the expression of TNFα and TNFR2 was higher in
early developing CL, resembling thereby their expression patterns de-
scribed previously [24]. The TNF-system was, however, not modulated
in response to the suppression of PGs synthesis.
4.3. Estrogen receptors
When expression of the estrogen receptors, ERα/ESR1 and ERβ/
ESR2, was examined, similarly to what has been observed for the PGR
[10], their mRNA levels remained unaffected by treatment with Pre-
vicox. Time-related changes in the expression of these two receptors in
the canine CL were shown previously [55]. In accordance with our
findings, here, the expression of ERα/ESR1 increased between luteal
formation and mid-diestrus. However, and in contrast to the previous
report, changes in ERβ/ESR2 were also found in this study, revealing its
increasing expression towards mid-diestrus. This difference could be
explained by the high variability in circulating levels of 17β-estradiol
(E2) [7], possibly exerting regulatory effects on its own receptors.
4.4. Factors involved in steroidogenesis
Knowing the importance of some key transcriptional factors in
regulating STAR expression, we decided to assess the basic capability of
luteal PGs to modulate their expression in the CL following the sup-
pression of prostaglandin synthesis. Among the five regulators studied
here (cJUN, SF1, GATA4, GATA6 and YY1), only cJUN expression was
affected by the treatment. The cJUN is a member of the AP1-family of
transcriptional factors, and is well known for its involvement in reg-
ulating STAR promoter activity [56]. In pregnant dogs, its luteal ex-
pression was suppressed towards prepartum luteolysis, mirroring the
diminishing STAR expression and circulating P4 levels at that time
[22]. Knowing this, it was perplexing to observe increased expression of
cJUN in response to Previcox treatment at day 20 after ovulation. A
similar effect was observed for CCNA2, which encodes for cyclin-A2
protein, a positive regulator of the cell cycle [57]. Since, clearly, as
observed in our previous studies, blocking COX2/PTGS2 led to a de-
crease in the size of luteal cell nuclei (indicating diminished tran-
scriptional activity), lower STAR expression and lowered P4 levels
[10,18], the upregulation of cJUN and CCNA2 in treated CL appears to
result from the presence of some, as yet undefined, compensatory me-
chanisms in the CL responding to the functional withdrawal of PGs. On
the other hand, since the mRNA expression of cJUN and CCNA2 was
examined here, it is thus possible that their functional availability is
regulated at the protein level or through post-translational modifica-
tions, such as phosphorylation [56].
4.5. Conclusions
Interestingly, in our study, most of the effects of Previcox treatment
on target gene expression were observed at days 20 and 30 after ovu-
lation. These days fall into the transitional stage between independence
and dependence on hypophyseal hormones for CL maintenance [14].
Afterwards, PRL is the main regulator of CL function [58–60]. On the
other hand, even though PRL is necessary for CL maintenance, and
together with LH its circulating concentrations continuously increase,
luteal regression still takes place. At the same time, during progression
of the luteal phase, the expression of PRLR in the CL decreases, re-
sembling the course of circulating P4 concentrations [59]. Conse-
quently, in view of our recent findings including the positive effects of
PGE2 on PRLR expression in lutein cells [10], and having noted the
suppressive effects of Previcox on PRLR expression in the CL, here a
new hypothesis is proposed: decreasing support of PGs during the go-
nadotropin-dependent luteal stage in the dog might lead to lowered
PRLR expression and contribute, thereby, to ongoing CL degeneration
and diminishing P4 levels.
Thus, indeed, the transition period between the two functional
stages of the canine CL appears to be of the utmost importance, marking
a change in the regulatory mechanisms of luteal function and the
transition between the developing CL, with a high steroidogenic output,
and the maintenance luteal stage exhibiting a slow degeneration of the
CL accompanied by a progressive decrease in P4 production.
In this context, the results of the present work indicate a modulatory
role of PGs that goes beyond the gonadotropin-independent phase, and
this despite the observed large variations in expression of several of our
target genes. These variations could be due to the limited number of
animals available per group and/or individual variations between these
animals. On the other hand, however, in particular in the CL of
Fig. 3. Expression of cJUN and CCNA2mRNA in luteal tissue samples of control and Previcox-treated dogs. Relative target gene expression was determined by
Real Time (TaqMan) PCR (Xg ± SD). The Kruskal-Wallis (non-parametric ANOVA) was applied to test the effects of time on gene expression in all control samples
revealing: P > 0.05 for cJun and P=0.001 for CCNA2. In case of CCNA2 it was followed by Dunn’s multiple comparison post-test (dotted line in B). Student’s t-test
was applied to test the effect of treatment on gene expression (solid lines). Bars with asterisks differ at: ** = P < 0.01.
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Table 1
Expression of target genes significantly affected by time. Relative gene expression (RGE) is presented for each control group as geometric mean and geometric
standard deviation (± SD). Kruskal–Wallis (non-parametric ANOVA) was applied, followed by Dunn’s test. Only comparisons with significant P-value at Dunn’s test
are represented. P < 0.05 was considered statistically significant.
Target Group RGE SD+/SD− ANOVA p Value Dunn’s test
ETB
Day 0 control 1 10.79/0.92
P=0.005
d0 vs d5 – P < 0.05
d0 vs d10 – P < 0.05
d0 vs d20 – P < 0.05
d0 vs d30 – P < 0.05
Day 5 control 26.6 13.82/9.1
Day 10 control 42.37 11.28/8.91
Day 20 control 35.55 28.66/15.87
Day 30 control 17.04 22.34/9.67
ET2
Day 0 control 5.92 16.57/4.36
P=0.03 d0 vs d10 – P < 0.05
Day 5 control 1.66 2.97/1.06
Day 10 control 0.99 0.74/0.42
Day 20 control 1.88 1.57/0.86
Day 30 control 1.86 3.76/1.25
ECE1
Day 0 control 1 0.77/0.43
P=0.03
d0 vs d20 – P < 0.01
d0 vs d30 – P < 0.01
d10 vs d20 – P < 0.05
d10 vs d30 – P < 0.05
Day 5 control 2.04 1.04/0.69
Day 10 control 1.45 0.79/0.51
Day 20 control 3.17 1.87/1.18
Day 30 control 2.88 2.27/1.27
eNOS
Day 0 control 1 1.07/0.52
P=0.02 d0 vs d20 – P < 0.05
Day 5 control 3.1 2.17/1.28
Day 10 control 2.16 0.34/0.29
Day 20 control 4.61 0.61/0.54
Day 30 control 2.94 5.06/1.86
iNOS
Day 0 control 1 0.91/0.48
P=0.02 d0 vs d20 – P < 0.05d0 vs d30 – P < 0.05
Day 5 control 1.82 1.22/0.73
Day 10 control 2.14 0.57/0.45
Day 20 control 3.78 2.33/1.44
Day 30 control 3.51 1.67/1.13
ERα/ESR1
Day 0 control 0.99 3.75/0.79
P=0.01 d0 vs d30 – P < 0.05
Day 5 control 2.46 1.59/0.97
Day 10 control 4.33 4.96/2.31
Day 20 control 5.2 1.27/1.02
Day 30 control 9.19 4.45/3
ERβ/ESR2
Day 0 control 1 0.65/0.39
P=0.001 d10 vs d30 – P < 0.01
Day 5 control 0.82 0.56/0.33
Day 10 control 0.44 0.25/0.16
Day 20 control 0.67 0.16/0.13
Day 30 control 1.24 0.67/0.44
YY1
Day 0 control 1 1.4/0.58
P=0.002 d0 vs d20 – P < 0.01
Day 5 control 2.39 1.52/0.93
Day 10 control 3.2 2.14/1.28
Day 20 control 3.43 0.52/0.45
Day 30 control 2.92 0.82/1.2
SF1
Day 0 control 1 1.45/0.59
P=0.004 d0 vs d20 – P < 0.05d0 vs d30 – P < 0.05
Day 5 control 2.11 1.27/0.79
Day 10 control 2.59 2.38/1.24
Day 20 control 3.08 1.44/0.98
Day 30 control 3.03 2.4/1.34
GATA6
Day 0 control 1.02 0.13/0.12
P=0.002 d5 vs d20 – P < 0.01d5 vs d30 – P < 0.05
Day 5 control 1.14 0.28/0.22
Day 10 control 0.91 0.35/0.25
Day 20 control 0.68 0.16/0.13
Day 30 control 0.61 0.51/0.28
END
Day 0 control 1 0.58/0.37
P=0.01 d0 vs d30 – P < 0.01
Day 5 control 1.7 0.44/0.35
Day 10 control 1.16 0.13/0.12
Day 20 control 2.21 0.86/0.62
Day 30 control 2.32 2.58/1.22
IL10
Day 0 control 1 2.71/0.73
P=0.03 d5 vs d30 – P < 0.05
Day 5 control 3.44 3.97/1.84
Day 10 control 2.27 1.5/0.91
Day 20 control 0.68 0.18/0.14
Day 30 control 0.77 0.1/0.09
(continued on next page)
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Previcox-treated animals, they could possibly also arise from the pre-
sence of some compensatory mechanisms, as indicated by the effects of
treatment on cJUN and CCNA2 expression. Since the tissue material
used for the present study derived from a closed study, we were not able
to include additional samples. In the present study, after consulting
with the manufacturer for drug safety, double the recommended ef-
fective dosage of Previcox was administered to the animals. Despite this
higher dosage, pharmacokinetics of firocoxib could reduce its local
concentrations at the ovary. This could affect the local effectiveness of
the drug, additionally contributing to the obtained variation.
Nevertheless, in the context of canine CL physiology, supported by our
previous reports [10,59], our observations seem encouraging for fur-
ther investigation into canine CL regulation.
Finally, supporting our hypothesis, the results presented herein,
summarized in Fig. 4, show some potential novel roles of PGs in reg-
ulation of the early canine CL, going beyond the P4-stimulatory effects.
The involvement of other COX2/PTGS2-derived metabolites on luteal
function in the dog remains to be elucidated. Changes induced by in-
hibition of COX2/PTGS2 in the expression of ANGPT family members
(regulators of vascular stability or disruption), seem to indicate a role of
PGs in blood vessel stabilization. Also, the increased expression of ET1
in treated animals, as well as of CD4 and pro-inflammatory interleukins,
point towards a (immuno)protective role of PGs in the maintenance of
CL function.
Having the life span of the CL divided into gonadotropin-dependent
and -independent phases, the dog appears to be an interesting model to
study mechanisms regulating CL function in a species in which the lu-
teal phase is not affected by possible masking effects of gonadotropins,
in particular during early CL development.
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Target Group RGE SD+/SD− ANOVA p Value Dunn’s test
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